Efficacy Studies CROs in United States

Global leader in providing preclinical and clinical laboratory services. Charles River offers early-stage discovery, safety assessment, and clinical support services to pharmaceutical and biotech companies worldwide.

Exton, Pennsylvania-based preclinical CRO providing in vivo PK/PD studies, ADME services, and GLP bioanalytical testing for small-molecule and biologic drug candidates.

GLP-compliant preclinical CRO in Austin, Texas, offering 100+ validated xenograft efficacy models, IND-enabling toxicology, and RNAi therapeutic development services.

Independent nonprofit applied science and technology organization providing preclinical research, inhalation toxicology, bioanalytical services, and pharmaceutical development support.

World's largest nonprofit R&D organization offering GLP-compliant preclinical safety, toxicology, inhalation studies, and bioanalytical services including BSL-3 biocontainment capabilities.

Preclinical CRO specialising in immunotoxicology and immune safety assessment, offering in vivo and in vitro studies for pharma, biotech, and government clients.

Preclinical CRO in Pennsylvania providing GLP and non-GLP toxicology, safety pharmacology, and pathology services with a focus on small and large molecule therapeutics.

AI-enabled precision oncology CRO using patient-derived xenograft models and ex vivo pharmacology to generate predictive therapeutic response data for drug developers.

Precision oncology CRO using patient-derived orthotopic xenograft models and predictive AI to guide drug selection and oncology development decisions.

Specialty CRO focused on translational oncology services. Champions provides patient-derived xenograft (PDX) tumor models, ex vivo tumor platforms, and oncology pharmacology studies.

Preclinical oncology CRO using patient-derived tumor models and TumorGraft technology for in vivo efficacy studies, providing translational research services for oncology drug development.

GLP-compliant preclinical CRO specializing in toxicology, pathology, and ADME studies for pharmaceutical, biotech, and agrochemical clients with full necropsy and histopathology capabilities.

LabCorp Drug Development preclinical and toxicology centre in Madison, Wisconsin, providing GLP-compliant general and genetic toxicology, safety pharmacology, and reproductive toxicology studies.

Translational oncology and metabolic disease CRO providing tumor models (PDX, syngeneic, humanized), oncology pharmacology, and biomarker services for drug discovery.

Research models and services provider offering genetically defined laboratory animals, contract research services, and scientific consulting for preclinical drug development.

Specialty CRO providing GLP-compliant anatomic pathology, histotechnology, and immunohistochemistry services for pharma, biotech, and government preclinical research programs.

Specialist preclinical ophthalmology CRO with AAALAC-accredited labs in Oklahoma City and Ann Arbor, providing pharmacology, PK/tox, bioanalysis, and formulation services for ocular drug development.

Kentucky-based preclinical CRO specialising in oncology efficacy studies using proprietary humanised rodent models and patient-derived xenografts for immuno-oncology drug development.

Independent not-for-profit preclinical CRO offering full IND-enabling GLP toxicology programs, inhalation toxicology, and immunogenicity testing from the Illinois Institute of Technology campus.

Contract research organization providing drug discovery and development services including preclinical safety assessment, bioanalytical services, and research animal models.

Not-for-profit preclinical CRO with ABSL-3 capabilities and expertise in inhalation toxicology, pulmonary delivery, and infectious disease models from 100+ acre campus.

Large preclinical CRO in Michigan acquired by Charles River Laboratories, providing GLP toxicology, safety pharmacology, and ADME studies in purpose-built facilities spanning over 800,000 sq ft.

Full-continuum preclinical CRO providing integrated in vitro and in vivo services including efficacy, toxicity, biodistribution, and product release studies in small and large animals.

Preclinical CRO specializing in in vitro pharmacology, receptor binding, enzyme inhibition assays, and ADME screening for drug discovery programs.

Specialty preclinical CRO focused on Asia-Pacific markets, providing preclinical safety assessment, pharmacology, and bioanalytical services for small molecule and biologic programs.

Specialty preclinical CRO focused on non-GLP ophthalmic and oncology efficacy studies, providing in vivo animal model services for ocular disease and solid tumor drug development.

Preclinical CRO specializing in CNS drug discovery using proprietary AI-powered behavioral phenotyping platforms for neurological and psychiatric disorders.

US subsidiary of Shin Nippon Biomedical Laboratories specializing in GLP preclinical safety assessment including general toxicology, reproductive toxicology, and inhalation studies with NHP and rodent capabilities.

Nonprofit research organization providing drug discovery, preclinical development, and analytical services with deep expertise in oncology and infectious disease including BSL-3 capabilities.

Independent GLP preclinical CRO and testing laboratory in Sugar Land, Texas, covering mammalian toxicology, aquatic, environmental, and animal health studies since 1975.

Oncology-focused CRO founded on the Mayo Clinic campus offering preclinical-to-clinical oncology development with PDX models, flow cytometry, and Phase I/II trial management.